StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.28−0.00 (-0.74%)

Close on Nov 17, 2026Market cap $53.58MP/E –Yield –

Heron Therapeutics cash

Cash and short-term investments held at the end of each period.

Heron Therapeutics's cash was $42.70M at Jun 30, 2026. For fiscal 2025 it was $46.60M, down 21.4% from the year before. Over ten years it grew -9.8% a year on average. The highest annual figure on record is $391.00M in fiscal 2019.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$46.60M-21.4%
FY2024Dec 31, 2024$59.30M-26.2%
FY2023Dec 31, 2023$80.40M-5.3%
FY2022Dec 31, 2022$84.90M-46.1%
FY2021Dec 31, 2021$157.60M-24.4%
FY2020Dec 31, 2020$208.50M-46.7%
FY2019Dec 31, 2019$391.00M+17.6%
FY2018Dec 31, 2018$332.40M+92.8%
FY2017Dec 31, 2017$172.40M+237.4%
FY2016Dec 31, 2016$51.10M-61.1%
FY2015Dec 31, 2015$131.20M+80.5%
FY2014Dec 31, 2014$72.68M+0.5%
FY2013Dec 31, 2013$72.29M+35.1%
FY2012Dec 31, 2012$53.51M+197.7%
FY2011Dec 31, 2011$17.97M+752.3%
FY2010Dec 31, 2010$2.11M-72.2%
FY2009Dec 31, 2009$7.59M-23.8%
FY2008Dec 31, 2008$9.97M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$42.70M+5.2%
Q1 FY2026Mar 31, 2026$44.80M-11.6%
Q4 FY2025Dec 31, 2025$46.60M-21.4%
Q3 FY2025Sep 30, 2025$55.50M-21.7%
Q2 FY2025Jun 30, 2025$40.60M-39.7%
Q1 FY2025Mar 31, 2025$50.70M-29.1%
Q4 FY2024Dec 31, 2024$59.30M-26.2%
Q3 FY2024Sep 30, 2024$70.90M-8.4%
Q2 FY2024Jun 30, 2024$67.30M+102.7%
Q1 FY2024Mar 31, 2024$71.50M+19.2%
Q4 FY2023Dec 31, 2023$80.40M-5.3%
Q3 FY2023Sep 30, 2023$77.40M-36.4%
Q2 FY2023Jun 30, 2023$33.20M-60.2%
Q1 FY2023Mar 31, 2023$60.00M-46.4%
Q4 FY2022Dec 31, 2022$84.90M-46.1%
Q3 FY2022Sep 30, 2022$121.70M-40.0%
Q2 FY2022Jun 30, 2022$83.50M-67.6%
Q1 FY2022Mar 31, 2022$111.90M-32.8%
Q4 FY2021Dec 31, 2021$157.60M-24.4%
Q3 FY2021Sep 30, 2021$202.80M-21.4%
Q2 FY2021Jun 30, 2021$257.70M-14.3%
Q1 FY2021Mar 31, 2021$166.50M-53.3%
Q4 FY2020Dec 31, 2020$208.50M-46.7%
Q3 FY2020Sep 30, 2020$258.10M+0.7%
Q2 FY2020Jun 30, 2020$300.80M+9.0%
Q1 FY2020Mar 31, 2020$356.30M+23.2%
Q4 FY2019Dec 31, 2019$391.00M+17.6%
Q3 FY2019Sep 30, 2019$256.30M-29.7%
Q2 FY2019Jun 30, 2019$276.00M-34.8%
Q1 FY2019Mar 31, 2019$289.20M+153.9%
Q4 FY2018Dec 31, 2018$332.40M+92.8%
Q3 FY2018Sep 30, 2018$364.80M+393.0%
Q2 FY2018Jun 30, 2018$423.00M+287.0%
Q1 FY2018Mar 31, 2018$113.90M-31.1%
Q4 FY2017Dec 31, 2017$172.40M+237.4%
Q3 FY2017Sep 30, 2017$74.00M-16.8%
Q2 FY2017Jun 30, 2017$109.30M–
Q1 FY2017Mar 31, 2017$165.20M–
Q4 FY2016Dec 31, 2016$51.10M–
Q3 FY2016Sep 30, 2016$88.90M–

More Heron Therapeutics figures

See a number that looks wrong?